ADC Drug Trial name (Identifier) Phase Indication/Patient population Active comparator Ref(s)
Lung cancer
Trastuzumab deruxtecan DESTINY-Lung01 (NCT03505710) II HER2-overexpressing or mutated, unresectable and/or metastatic NSCLC None [@111530; @111531]
Datopotamab deruxtecan TROPION-Pan Tumor01 (NCT04656652) III Previously treated advanced or metastatic NSCLC without actionable genomic alterations Docetaxel [@111532]
TROPION-Lung05 (NCT04484142) II Advanced or metastatic NSCLC with actionable genomic alterations and progression on or after applicable targeted therapy and platinum-based CT None [@111578]
Patritumab deruxtecan (NCT03260491) I Metastatic or unresectable NSCLC None [@111533; @111534]
Telisotuzumab vedotin (NCT03539536) II Previously treated c-Met-positive NSCLC None [@111535]
Gastrointestinal cancer
Trastuzumab deruxtecan DESTINY-CRC01 (NCT0338490) II HER2-expressing advanced colorectal cancer None [@111536; @111537]
DESTINY-Gastric02 (NCT04014075) II Unresectable or metastatic gastric or GEJ adenocarcinoma in patients who have progressed on or after a trastuzumab-containing regimen None [@111538]
Cervical cancer
Tisotumab vedotin NCT03438396 II Previously treated, recurrent or metastatic cervical cancer None [@111524]
Breast cancer
Lifastuzumab vedotin ACE-Breast03 (NCT04829604) II Heavily pretreated HER2-positive metastatic BC patients resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens None [@111540]
Trastuzumab duocarmazine SYD985.002/TULIP (NCT03262935) III Locally advanced or metastatic HER2+ BC (≥2L) Physician's choice [@111528]
Other cancers
Lifastuzumab vedotin (NCT01363947) I NSCLC and platinum-resistant ovarian cancer None [@111539]
Trastuzumab deruxtecan (NCT04482309) II HER2 expressing solid tumors including bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, rare tumors None [@111579]
DESTINY-PanTumor02 (NCT04482309) II Patients with selected HER2 expressing solid tumors None [@111542]
Disitamab vedotin (monotherapy and in combination) (NCT04879329) II HER2-expressing urothelial cancer None [@111580]
(NCT05113459) II Neoadjuvant treatment of locally advanced gastric or GEJ adenocarcinoma with moderate and high expression of HER2 None
(NCT05016973) II In combination with triplizumab as a preoperative neoadjuvant therapy for myometrial invasive bladder cancer (MIBC) None
Ladiratuzumab vedotin (NCT04032704) II Different types of solid tumors None [@111541]
Mirvetuximab soravtansine MIRASOL (NCT04209855) III Platinum-resistant high-grade ovarian cancer with high folate receptor expression Physician choice chemotherapy [@111552]